Dimerix expands COVID-19 study into Australia
Dimerix expands COVID-19 study into Australia
General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.
About this video
Nina Webster, CEO of Dimerix joins ausbiz to discuss its agreement with the University of Sydney to expand its CLARITY 2.0 clinical study into Australia. Even as vaccine rates increase, Nina says it is anticipated that a significant portion of the population will remain suceptible to COVID-19 because they are not vaccinated or do not get an adequate protective response from the vaccine. It is likely a large number of people will get infected, says Nina, and there remains a great need for treatments for patients with COVID-19 in Australia. The study will test Dimerix's drug candidate DMX-200 in COVID-19 patients with respiratory complications. Once regulatory and ethics approval is received, Nina says an initial six sites will begin recruitment for the study across New South Wales, Victoria and Queensland. Click to find out the timeline for the drug.